JP2013528230A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528230A5 JP2013528230A5 JP2013514402A JP2013514402A JP2013528230A5 JP 2013528230 A5 JP2013528230 A5 JP 2013528230A5 JP 2013514402 A JP2013514402 A JP 2013514402A JP 2013514402 A JP2013514402 A JP 2013514402A JP 2013528230 A5 JP2013528230 A5 JP 2013528230A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition
- administration
- cells
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 80
- 239000000203 mixture Substances 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 67
- 210000003414 extremity Anatomy 0.000 claims description 36
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims description 20
- 206010034576 Peripheral ischaemia Diseases 0.000 claims description 20
- 230000000250 revascularization Effects 0.000 claims description 20
- 230000004083 survival effect Effects 0.000 claims description 19
- 230000000302 ischemic effect Effects 0.000 claims description 18
- 206010052428 Wound Diseases 0.000 claims description 16
- 208000027418 Wounds and injury Diseases 0.000 claims description 16
- 238000002266 amputation Methods 0.000 claims description 16
- 206010017711 Gangrene Diseases 0.000 claims description 15
- 206010053648 Vascular occlusion Diseases 0.000 claims description 15
- 230000007423 decrease Effects 0.000 claims description 15
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 12
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 12
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 12
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 12
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 12
- 230000036407 pain Effects 0.000 claims description 12
- 241000204031 Mycoplasma Species 0.000 claims description 10
- 229940098773 bovine serum albumin Drugs 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 238000011109 contamination Methods 0.000 claims description 10
- 230000003511 endothelial effect Effects 0.000 claims description 10
- 239000002158 endotoxin Substances 0.000 claims description 10
- 230000000813 microbial effect Effects 0.000 claims description 10
- 230000017423 tissue regeneration Effects 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 230000033001 locomotion Effects 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 238000004393 prognosis Methods 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- 230000029663 wound healing Effects 0.000 claims description 8
- 230000000202 analgesic effect Effects 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 206010028851 Necrosis Diseases 0.000 claims description 6
- 230000033115 angiogenesis Effects 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 230000008602 contraction Effects 0.000 claims description 6
- 230000034994 death Effects 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 6
- 230000008021 deposition Effects 0.000 claims description 6
- 230000037313 granulation tissue formation Effects 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000017074 necrotic cell death Effects 0.000 claims description 6
- 238000007634 remodeling Methods 0.000 claims description 6
- 230000003833 cell viability Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 210000002683 foot Anatomy 0.000 claims description 4
- 210000005087 mononuclear cell Anatomy 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 230000000284 resting effect Effects 0.000 claims description 4
- 230000035488 systolic blood pressure Effects 0.000 claims description 4
- 210000003371 toe Anatomy 0.000 claims description 4
- 230000036269 ulceration Effects 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 2
- 238000002583 angiography Methods 0.000 claims description 2
- 210000003423 ankle Anatomy 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 238000009556 duplex ultrasonography Methods 0.000 claims description 2
- 239000008151 electrolyte solution Substances 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 239000012894 fetal calf serum Substances 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 238000002355 open surgical procedure Methods 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000004233 talus Anatomy 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 63
- 230000011132 hemopoiesis Effects 0.000 claims 5
- 201000002818 limb ischemia Diseases 0.000 claims 4
- 230000035899 viability Effects 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 description 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35351210P | 2010-06-10 | 2010-06-10 | |
| US61/353,512 | 2010-06-10 | ||
| PCT/US2011/040087 WO2011156784A1 (en) | 2010-06-10 | 2011-06-10 | Compositions and methods of treating no-option critical limb ischemia (cli) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013528230A JP2013528230A (ja) | 2013-07-08 |
| JP2013528230A5 true JP2013528230A5 (https=) | 2014-07-31 |
Family
ID=44246418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514402A Pending JP2013528230A (ja) | 2010-06-10 | 2011-06-10 | ノーオプション重症虚血肢（ｃｌｉ）を処置するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120100108A1 (https=) |
| EP (1) | EP2579882A1 (https=) |
| JP (1) | JP2013528230A (https=) |
| AU (1) | AU2011265194A1 (https=) |
| CA (1) | CA2802203A1 (https=) |
| WO (1) | WO2011156784A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140099292A1 (en) * | 2012-03-23 | 2014-04-10 | Aastrom Biosciences, Inc. | CD14+ Cell Compositions and Methods of Using Same |
| CA2868032A1 (en) * | 2012-03-23 | 2013-09-26 | Aastrom Biosciences, Inc. | Cell compositions and methods of using same |
| US20150064141A1 (en) | 2012-04-05 | 2015-03-05 | The Regents Of The University Of California | Regenerative sera cells and mesenchymal stem cells |
| WO2014089397A1 (en) * | 2012-12-06 | 2014-06-12 | Aastrom Biosciences, Inc. | Compositions and methods of treating and preventing pulmonary fibrosis |
| US10331856B1 (en) * | 2012-12-19 | 2019-06-25 | One Call Care Management | Physical therapy patient treatment monitoring systems and methods |
| WO2016140716A1 (en) | 2015-03-02 | 2016-09-09 | The Trustees Of Columbia University In The City Of New York | Injectable microtissue systems, devices, and methods |
| CN107949390A (zh) * | 2015-05-01 | 2018-04-20 | 赛斯卡医疗有限公司 | 用于治疗的自体骨髓的肌内施用 |
| US10456423B2 (en) | 2016-06-13 | 2019-10-29 | SMART SURGICAL, Inc. | Compositions for biological systems and methods for preparing and using the same |
| US10426796B2 (en) * | 2016-06-13 | 2019-10-01 | SMART SURGICAL, Inc. | Compositions for biological systems and methods for preparing and using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070023302A1 (en) | 2005-07-29 | 2007-02-01 | Nationalpak Limited | Watch box with back-up effective security locker and warranty compartment |
| US9598673B2 (en) * | 2006-05-19 | 2017-03-21 | Creative Medical Health | Treatment of disc degenerative disease |
| CA2913024A1 (en) | 2006-11-03 | 2008-05-08 | Aastrom Biosciences, Inc. | Mixed cell populations for tissue repair and separation technique for cell processing |
-
2011
- 2011-06-10 CA CA2802203A patent/CA2802203A1/en not_active Abandoned
- 2011-06-10 AU AU2011265194A patent/AU2011265194A1/en not_active Abandoned
- 2011-06-10 EP EP11726304.6A patent/EP2579882A1/en not_active Withdrawn
- 2011-06-10 US US13/158,298 patent/US20120100108A1/en not_active Abandoned
- 2011-06-10 WO PCT/US2011/040087 patent/WO2011156784A1/en not_active Ceased
- 2011-06-10 JP JP2013514402A patent/JP2013528230A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528230A5 (https=) | ||
| Wong et al. | Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial | |
| Xie et al. | Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial | |
| Powell et al. | Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia | |
| EP1696900B1 (en) | Use of treprostinil to treat ischemic lesions | |
| Lei et al. | Multiple-dose intravenous tranexamic acid further reduces hidden blood loss after total hip arthroplasty: a randomized controlled trial | |
| Reed et al. | Uses of tranexamic acid | |
| Barrachina et al. | Tranexamic acid compared with placebo for reducing total blood loss in hip replacement surgery: a randomized clinical trial | |
| Karaaslan et al. | Reducing blood loss in simultaneous bilateral total knee arthroplasty: combined intravenous–intra-articular tranexamic acid administration. A prospective randomized controlled trial | |
| Huang et al. | Downregulation of microRNA‐155 stimulates sevoflurane‐mediated cardioprotection against myocardial ischemia/reperfusion injury by binding to SIRT1 in mice | |
| Lawall et al. | Efficacy and safety of alprostadil in patients with peripheral arterial occlusive disease fontaine stage IV: results of a placebo controlled randomised multicentre trial (ESPECIAL) | |
| Chen et al. | Efficacy and safety of perioperative tranexamic acid in elderly patients undergoing trochanteric fracture surgery: a randomised controlled trial | |
| Pineda-Cortel et al. | Biotherapeutic applications of platelet-rich plasma in regenerative medicine | |
| Liu et al. | Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial | |
| Xu et al. | Clinical observation of the application of autologous peripheral blood stem cell transplantation for the treatment of diabetic foot gangrene | |
| Liu et al. | TSLP promote M2 macrophages polarization and cardiac healing after myocardial infarction | |
| Skóra et al. | Transplantation of autologous bone marrow mononuclear cells with VEGF gene improves diabetic critical limb ischaemia | |
| Loewe et al. | Venous thromboembolic disease | |
| Paraskevas et al. | Thromboangiitis obliterans (Buerger’s disease): searching for a therapeutic strategy | |
| JP7516045B2 (ja) | 筋骨格疾患のための再生・細胞療法 | |
| Ackery et al. | Tranexamic acid for trauma-related hemorrhage | |
| CN114191450B (zh) | 普鲁士蓝及其类似物在制备预防、延缓或治疗骨质疏松症药物中的应用 | |
| Borgen et al. | Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA | |
| Wang et al. | Effect of repeated intravenous tranexamic acid in the perioperative period of proximal femoral nail antirotation for femoral intertrochanteric fracture | |
| Filardo et al. | Cartilage lesions and osteoarthritis of the knee: biologics |